Search Results

Affinivax, Inc. (“Affinivax”) and Astellas Pharma Inc. (“Astellas”) today announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae.

The week began with positive updates in the vaccine development space against various infectious diseases from Emergent, Merck, Affinivax and Ocugen.

GSK announced that it is acquiring Affinivax for up to $3.3 billion to gain its novel class of developmental vaccines and its MAPS technology.

Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) technology platform, today announced the appointment of Dr. Rick Malley as Chief Scientific Officer.

Affinivax, Inc. today announced the appointment of Vanya Sagar, M.P.A., as its Chief People Officer.

Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Steven Brugger, president and CEO of Affinivax, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:30 a.m. ET.

Affinivax, Inc. today announced the company will present a poster highlighting COVID-19 MAPS™ vaccine non-human primate data at IMMUNOLOGY2022™, the annual meeting of the American Association of Immunologists (AAI) in Portland, Oregon (May 6-10, 2022.

Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform , today announced that Elizabeth Radcliffe has joined the company as Chief Financial Officer.

Affinivax, Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ platform, announced that Kara Bickham, MD, has joined the company as Chief Medical Officer.

Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Stuart Chaffee, PhD, has joined the company as Chief Business Officer.